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Abstract
Background: The implementation of high-sensitivity cardiac troponin T (hs-cTnT) assays and  
a cutoff based on the 99th cTnT percentile in the evaluation of patients with suspected acute coronary 
syndrome has not been uniform due to uncertain effects on health benefits and utilization of limited 
resources.
Methods: Clinical and laboratory data from patients with chest pain or dyspnea at the emergency de-
partment (ED) were evaluated before (n = 20516) and after (n = 18485) the lowering of the hs-cTnT 
cutoff point from 40 ng/L to the 99th hs-cTnT percentile of 14 ng/L in February 2012. Myocardial 
infarction (MI) was diagnosed at the discretion of the attending clinicians responsible for the patient. 
Results: Following lowering of the hs-cTnT cutoff point fewer ED patients with chest pain or dyspnea 
as the principal complaint were analyzed with an hs-cTnT sample (81% vs. 72%, p < 0.001). Overall 
30-day mortality was unaffected but increased among patients not analyzed with an hs-cTnT sample 
(5.3% vs. 7.6%, p < 0.001). The MI frequency was unchanged (4.0% vs. 3.9%, p = 0.72) whereas 
admission rates decreased (51% vs. 45%, p < 0.001) as well as hospital costs. Coronary angiographies 
were used more frequently (2.8% vs. 3.3%, p = 0.004) but with no corresponding change in coronary 
interventions. 
Conclusions: At the participating hospital, lowering of the hs-cTnT cutoff point to the 99th percentile 
decreased admissions and hospital costs but did not result in any apparent prognostic or treatment 
benefits for the patients. (Cardiol J 2017; 24, 6: 612–622)
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When the electrocardiogram is inconclusive, 
the diagnosis of non-ST-segment elevation myo-
cardial infarction (NSTEMI) relies on the level 
and the change in heart damage biomarker cardiac 
troponin [1]. Several reports indicate that the use 
of high-sensitivity cardiac-specific troponin assays 
and diagnostic cutoff points based on the 99th 
troponin percentile value in healthy populations, 
as advocated by the third universal definition of 
myocardial infarction (MI), results in improved 
diagnostic accuracy and an ability to find patients 
with a poor prognoses who may benefit from in-
tervention [2–7]. Despite this, the implementation 
of high-sensitivity troponin assays has not been 
uniform, due, in part, to the suspicion that a low-
ering of the diagnostic cutoff point will inundate 
hospitals with patients with no apparent benefit 
from cardiologic interventions [8]. 
Due, in part, to this controversy the diagnostic 
cutoff point for MI, based on the 4th generation 
cTnT assay imprecision, remained unchanged at 
40 ng/L when the high-sensitivity cardiac troponin T 
(hs-cTnT) assay was introduced in clinical routine 
at the hospital of this study. For this reason, levels 
above 40 ng/L were regarded as the diagnostic 
cutoff point for MI for 25 months, although the 
clinical hs-cTnT assay was capable of measuring 
the 99th hs-cTnT percentile of 14 ng/L [9] with 
a coefficient of variation (CV) below 10% and values 
down to 5 ng/L were reported to clinicians. After 
this 25-month period, the diagnostic cutoff point for 
MI was lowered to the 99th hs-cTnT percentile of 
14 ng/L, with the same hs-cTnT assay in use [10], 
and clinical routines for suspected ischemic coro-
nary disease were changed with hs-cTnT levels 
down to 5 ng/L reported to the attending clinician. 
The aim was to evaluate how lowering of the 
hs-cTnT diagnostic cutoff point for NSTEMI from 
40 ng/L to the 99th hs-cTnT percentile value of 
14 ng/L affected 30-day mortality, admission rates 
and resource utilization in patients with a chief 
complaint of chest pain or dyspnea in the emer-
gency department (ED). 
Methods
Study design and populations
Patients with at least one visit to the EDs 
at the Sahlgrenska University Hospital (Östra or 
Mölndal hospitals) with a chief complaint of chest 
pain or dyspnea between January 2010, and Decem-
ber 2013, were included in the study. Character-
ization of patients with chest pain from these EDs 
from another time period has been published before 
[11]. No exclusion criteria were used (Fig. 1). 
These ED’s did not have any point of care cTn 
analysis in use during the study period and all cTn 
evaluations were done using the hs-cTnT assay in 
the central laboratory. 
Study data were retrieved from the hospital’s 
administrative database containing diagnoses, inter-
ventions and hospital costs for each admission, from 
the National Board of Health and Welfare’s National 
Patient Register [12, 13], and Prescribed Drug Regis-
ter with information on hospital stays and medications 
[14]. Information on hs-cTnT levels was retrieved 
from the hospital´s laboratory database.
Data entered in to the local hospital database 
is used to partition funds within the hospital, thus 
adding an economic incentive for departments to 
keep this record complete. 
Entry of ordering time and patient identity in 
the laboratory database is a part of the test order-
ing procedure and is automatic. It is not possible 
to obtain a test result from the central lab without 
a complete registration. 
Table 1 (patient characteristics) shows data on 
diagnoses and medications reported to the Swed-
ish National Board of Health and Welfare between 
2010 and 2013. Diagnoses were classified based on 
ICD-codes. The definition of an “I-diagnose” was 
having an ICD-10 code beginning with “I”. I10 was 
defined as hypertension, I50 as heart failure, I48 as 
atrial fibrillation or flutter, J44 as chronic obstructive 
pulmonary disease (COPD), an ICD-code beginning 
with “E1” as diabetes and I63 as cerebral infarction.
Figure 1. Graphical presentation of the collection of the 
study group. Cohort 1 was collected using 40 ng/L as 
the high-sensitivity cardiac troponin T (hs-cTnT) cutoff 
and Cohort 2 using 14 ng/L as the hs-cTnT cutoff; ED — 
emergency department.
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Medications were classified using ATC-codes. 
C07 was defined as beta-blockers, C08 as calcium 
channel blockers, C09A as angiotensin converting 
enzyme inhibitors, C03DA as aldosterone antago-
nists, C03C as loop diuretics, B01AC06 as acetylic 
acid, B01AA as vitamin K inhibitors, C10AA as 
statins, A10A as insulin and A10B as other glucose 
lowering medications
Details of the hs-cTnT cutoff change
The 10th of December 2009 the hs-cTnT assay 
was introduced simultaneously at Östra University 
Hospital and at the Mölndal Hospital and levels 
down to 5 ng/L was reported. The previous cutoff 
based on the 4th generation cTnT assay limit of 
quantification of 40 ng/L (CV < 10%) was kept 
unchanged until the end of January 2012.
In February 2012, the hs-cTnT cutoff point 
for NSTEMI was changed to the 99th percentile of 
14 ng/L, as recommended by the European Society 
of Cardiology, but with continued use of the same 
hs-cTnT assay. At the same time, local guidelines 
at Sahlgrenska University Hospital for patients with 
suspected acute coronary syndrome (ACS) were 
changed to adapt to the new cutoff point (transla-
tion in supplementary data — see journal web-
site). The new medical protocol stressed the need 
for clinical judgment before an hs-cTnT was ordered, 
especially in patients not considered for chest pain 
suggesting myocardial ischemia. In addition, the new 
medical protocol listed alternative conditions other 
than NSTEMI that could cause hs-cTnT elevations.
Patients with NSTEMI were diagnosed at the 
discretion of the attending clinician by reviewing 
available clinical and laboratory data collected dur-
ing the hospital stay. 
The study was approved by the Ethics Com-
mittee at the University of Gothenburg, and the 
study protocol followed the ethical guidelines of 
the 1975 Declaration of Helsinki.
Laboratory methods
High-sensitivity cTnT was measured using 
the Elecsys® hs-cTnT immunoassay on a fully au-
tomated Modular® Analytics E170. The within-run, 
between-run and long-term CV have been published 
previously [15]. During the study Roche, the manu-
facturer of the hs-cTnT assay, made an error in the 
calibration routines which resulted in a lowered 
measure of cTnT concentration, specifically around 
the 14 ng/L level during the period of January 2011 
until May 2012. The local cTnT control based on 
pooled patient samples had a measured cTnT con-
centration of 15.8 ng/L in December 2009 when the 
hs-cTnT assay was introduced into the routine. The 
same pooled sera gave a measured cTnT concentra-
tion of 12.1 ng/L January 2011 and 17.9 ng/L after 
introduction of appropriate manufacturing routines 
at Roche May 2012 [10]. After May 2012 there was 
no observed significant drift of the hs-cTnT assay 
throughout the rest of the study period. Hs-cTnT 
values above the limit of quantification (LoQ) of 
5 ng/L were reported to clinicians throughout the 
study. For each patient, all hs-cTnT analyses dur-
ing the hospital stay were obtained from the local 
clinical chemistry database. The attending clinician 
made all decisions about the number of and timing 
of hs-cTnT sampling, based on clinical need.
Statistical analyses and calculations
The absolute hs-cTnT change during hospital 
stay was calculated as an absolute value of the differ-
ence between baseline hs-cTnT level and hs-cTnT 
level deviating the most from the level recorded 
during hospital stay. The hs-cTnT relative change 
during hospital stay was calculated as an absolute 
hs-cTnT change divided by baseline hs-cTnT level 
recorded during hospital stay multiplied by 100.
Dichotomous values were compared using 
exact tests with MonteCarlo estimates. Medians 
were compared using median tests and means us-
ing independent sample t-tests. 
All statistical analyses were performed using 
SPSS version 21. All probabilities were two-tailed, 
and p values < 0.05 were regarded as significant.
Results
Study population
The study cohort comprised of 21576 unique 
patients who were accountable for 39001 visits 
to the ED, and had in total 58524 hs-cTnT levels 
analyzed during the study period. During 2010 
until the end of January 2012, when hs-cTnT cutoff 
point for NSTEMI was kept at 40 ng/L, a total of 
13215 unique patients had 20516 visits for chest 
pain or dyspnea to the ED and 32167 hs-cTnT 
levels analyzed (Cohort 1). After the lowering of 
the hs-cTnT cutoff point in February 2012, and the 
change to the medical protocol for suspected ACS, 
11185 unique patients were analyzed with 26357 
hs-cTnT analyses at 18485 visits during February 
2012 to December 2013 (Cohort 2). 
Characteristics of the study cohorts before 
and after hs-cTnT cutoff point change
After lowering of  hs-cTnT cutoff point (Fig. 1), 
there was no change in age and gender distribu-
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tion among patients in the ED with a primary 
complaint of chest pain or dyspnea (Table 1). 
There were some small but statistically significant 
differences in cohorts before and after the cut-off 
change: 1. Proportion of patients with dyspnea 
decreased slightly (38% vs. 36%, p < 0.001). 
2. Small increases or decreases were also observed 
in the frequency of heart failure, diabetes mellitus, 
COPD, cerebral infarction and use of medications 
relevant for heart disease. There was however, no 
overall change in frequency of patients with diag-
noses related to cardiovascular disease (ICD-10 I- 
-diagnoses).
Overall changes after lowering  
the hs-cTnT cutoff point
After lowering of hs-cTnT cutoff point admis-
sion frequency decreased (58.8% vs. 52.8%, p < 
< 0.001; Table 2). After the lowering of the hs-cTnT 
cutoff point, fewer patients were analyzed with an 
hs-cTnT sample (81% vs. 72%, p < 0.001). How-
ever, admissions also decreased among patients 
who were analyzed with an hs-cTnT sample in 
the ED, despite increases in baseline hs-cTnT 
levels and increased frequency of slightly el-
evated baseline hs-cTnT levels (14–40 ng/L). 
The frequency of return to the ED within 30 days 
(Tables 2–4) and frequency of MI among return-
ers increased (Cohort 1: 0.51%, Cohort 2: 0.69% 
MI among patients who returned within 30 days, 
p = 0.021).
There was no overall change in the frequency 
of NSTEMI (4.0% vs. 3.9%, p = 0.72) or unstable 
angina pectoris diagnoses (Table 2). However, 
the NSTEMI diagnoses increased among patients 
with a baseline hs-cTnT between 14 ng/L and 
40 ng/L (Fig. 2B). Coronary angiographies increased 
(2.8% vs. 3.3%, p = 0.004) with no corresponding 
increase in percutaneous coronary interventions 
(1.3% vs. 1.2%, p = 0.60). 
Table 1. Characterization of patients with chest pain or dyspnea as principal complaint on the emergency 
department before (Cohort 1) or after (Cohort 2) lowering the high-sensitivity cardiac troponin T  
(hs-cTnT) cutoff. 
Cohort 1  Cohort 2 P
Number of emergency department visits 20516 18485
Demographics
Age [years] 67 (51–80) 68 (51–80) 0.46
Male sex 49.1% 49.9% 0.11
Dyspnea 38.0% 36.2% < 0.001
Diagnoses#
I-diagnoses* 69% 69% 0.39
Hypertension 44% 45% 0.0089
Heart failure 26% 24% < 0.001
Atrial fibrillation or flutter 25% 25% 0.13
Chronic obstructive pulmonary disease 19% 18% 0.0087
Diabetes mellitus 18% 17% 0.013
Cerebral infarction 6% 7% 0.0005
Drugs#
Beta-blockers 58% 59% 0.057
Calcium channel blockers 33% 35% 0.0013
ACE inhibitors 34% 36% 0.0044
Aldosterone antagonists 14% 13% 0.065
Loop diuretics 41% 39% < 0.001
Acetylic acid 49% 47% 0.015
Vitamin K antagonists 16% 18% < 0.001
HMG CoA reductase Inhibitors 41% 44% < 0.001
Insulin 10% 9% 0.02
Other glucose lowering therapy 12.5% 12.4% 0.73
#Data between 2010 and 2013 from the Swedish National Board of Health and Welfare; *ICD-10 code beginning with ”I”; ACE — angiotensin-
-converting enzyme
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All-cause mortality was unchanged in the 
entire cohort. However, the mortality increased 
among patients who were not analyzed with an 
hs-cTnT sample (Table 2, Fig. 2C). Patients who 
were not analyzed with an hs-cTnT sample were 
older (Cohort 1:65 years, Cohort 2:68 years, 
p < 0.001) and had more comorbidity (≥ 2 of heart 
failure, atrial fibrillation, COPD or stroke: Cohort 1: 
29%, Cohort 2: 33%, p < 0.001). The mortality 
decreased among patients who were analyzed 
with at least one hs-cTnT level in the ED (30 day 
mortality 3.9% vs. 2.9%, p < 0.001). 
Subgroup analysis of ED patients  
with chest pain or dyspnea
In addition to overall changes, subgroup analy-
sis of chest pain patients showed decreased fre-
quency of NSTEMI if baseline hs-cTnT was above 
40 ng/L in cohort 2 (Table 3, Fig. 2B). 
Patients with dyspnea were older, had higher 
baseline hs-cTnT levels, were more often admit-
ted, had higher frequencies of heart failure and 
higher mortality, compared with chest pain patients 
(Table 4). After lowering the hs-cTnT cutoff point, 
the hs-cTnT sampling frequency decreased by over 
a third in dyspnea patients (Fig. 2A) together with 
a borderline significant decrease in the NSTEMI 
frequency (Table 3).
The non-sampled patient group was older and 
had more comorbidity after lowering the hs-cTnT 
cutoff (Fig. 2C, D, Table 4). The increase in 30-day 
mortality among patients not analyzed with an 
hs-cTnT was especially prominent among dyspnea 
patients (Table 3, Fig. 2C).
Table 2. Characteristics of patients with chest pain or dyspnea as principal complaint at the emergency 
department before (Cohort 1) or after (Cohort 2) lowering the high-sensitivity cardiac troponin T (hs-cTnT) 
cutoff. 
Cohort 1 Cohort 2 P 
Admission 58.8% 52.8% < 0.001
Hospital cost among admitted (mean DRG weigh/chest pain 
or dypnea patient visit)
0.46 0.25 < 0.001
Admission if hs-cTnT analyzed on ED 71.3% 66.3% < 0.001
Admission time (days ± SD) 4.2 ± 4.8 4.1 ± 4.5 0.11
hs-cTnT sampling frequency 80.9% 71.7% < 0.001
Median baseline hs-cTnT level [ng/L] 6 (3–22) 9 (5–22) < 0.001
Baseline hs-cTnT level 14–40 ng/L among analysed on ED 19.7% 23.5% < 0.001
Return to emergency department within 30 days 25.9% 30.2% < 0.001
NSTEMI diagnosis†
NSTEMI 4.0% 3.9% 0.72
NSTEMI if baseline hs-cTnT 14–40 ng/L 4.9% 7.4% < 0.001
NSTEMI if baseline hs-cTnT > 40 ng/L 24.2% 23.1% 0.40
Primary or secondary diagnosis†
Unstable AP 1.1% 1.0% 0.58
Stable AP 4.9% 4.4% 0.048
Heart failure 6.2% 5.4% < 0.001
Interventions
Coronary angiography 2.8% 3.3% 0.004
Percutaneous coronary intervention 1.3% 1.2% 0.56
All cause mortality
30 day 3.9% 3.9% 0.98
180 day 9.6% 10.1% 0.13
All cause mortality if not analyzed with hs-cTnT
30 day 3.8% 5.8% < 0.001
180 day 11.7% 16.4% < 0.001
†Only patients that were admitted; AP — angina pectoris; DRG — diagnosis related group, a way to assess the hospital coast related to  
different diagnosis group; ED — emergency room; NSTEMI — non-ST-segment elevation myocardial infarction
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Subanalysis of patients with NSTEMI
There was no overall change in NSTEMI di-
agnoses after lowering the hs-cTnT cutoff. Median 
hs-cTnT levels among patients with NSTEMI were 
lower after implementation of 14 ng/L as the hs-cTnT 
cutoff point (Table 5) and more often remained 
below 40 ng/L throughout hospital stay (Fig. 3). 
The mortality among patients with NSTEMI was 
unchanged (Table 5).
Discussion
After lowering the hs-cTnT diagnostic cutoff 
point from 40 ng/L to the 99th hs-cTnT percentile 
of 14 ng/L, hs-cTNT sampling frequency and ad-
missions decreased with a neutral effect on overall 
mortality and NSTEMI frequency among patients 
visiting the ED with suspected ACS at this hospital. 
However, increased mortality was observed among 
Table 3. Characteristics of patients with chest pain as principal complaint on the emergency department 
before (Cohort 1) or after (Cohort 2) lowering the high-sensitivity cardiac troponin T (hs-cTnT) cutoff. 
Chest pain
Cohort 1 Cohort 2 P 
Number of ED visits 12714 11794
Age [years] 61 (47-76) 63 (47-75) 0.007
Male sex 51.4% 52.5% 0.086
Dyspnea NA NA NA
Admission 51.1% 45.1% < 0.001
Hospital cost among admitted (mean DRG weigh/patient visit) 0.33 0.18 < 0.001
Admission if hs-cTnT analyzed on ED 52.1% 45.9% < 0.001
Admission time (days ± SD) 3.2 ± 4.1 3.2 ± 3.6 0.65
hs-cTnT sampling frequency 90.1% 88.4% < 0.001
Median baseline hs-cTnT level [ng/L] 3 (3–13) 8 (4–16) < 0.001
Baseline hs-cTnT level 14–40 ng/L among analysed on ED 14.5% 20.3% < 0.001
Return to ED within 30 days 23.4% 28.8% < 0.001
NSTEMI diagnosis†
NSTEMI 5.0% 5.1% 0.79
NSTEMI if baseline hs-cTnT 14–40 ng/L 8.1% 9.7% 0.098
NSTEMI if baseline hs-cTnT > 40 ng/L 42.5% 33.6% < 0.001
Primary or secondary diagnosis†
Unstable AP 1.6% 1.5% 0.539
Stable AP 7.2% 6.4% 0.008
Heart failure 2.0% 1.7% 0.066
Interventions†
Coronary angiography 4.0% 4.5% 0.039
Percutaneous coronary intervention 2.0% 1.8% 0.28
All cause mortality
30 day 1.1% 1.1% 0.95
180 day 3.6% 4.2% 0.037
All cause mortality if not analyzed with hs-cTnT
30 day 0.6% 0.9% 0.39
180 day 2.8% 5.0% 0.004
†Only patients that were admitted; AP — angina pectoris; DRG — diagnosis related group, a way to assess the hospital coast related to  
different diagnosis group; ED — emergency room; NA — not applicable; NSTEMI — non-ST-segment elevation myocardial infarction 
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patients that were not analyzed with an hs-cTnT 
sample. This study is a service report and there-
fore, it is not possible to prove a cause and effect 
relationships. It is however, speculated that a lower 
hs-cTnT cutoff point resulted in a sampling bias so 
patients at high risk of non-specific hs-cTnT eleva-
tions were sampled less frequently after lowering 
the cutoff. This could result in bias toward older 
patients with several comorbidities that resulted in 
higher mortality in the non-sampled group. 
The present findings differ from previous 
studies of ED patients following the implementa-
tion of a lower cTn cutoff point where an increased 
NSTEMI frequency [16–18] and lower mortality 
[16] were found. These studies only included ED 
patients who were analyzed with a cTn sample [16, 
19] or admitted as high risk patients [17, 18]. In 
this study, all patients who came to the ED with 
chest pain or dyspnea were included. This  allowed 
for an examination of whether a different cohort 
was sampled when the hs-cTnT cutoff point was 
lowered. 
In agreement with previous studies, it was 
also found that the NSTEMI frequency increased 
Table 4. Characteristics of patients with dyspnea as principal complaint on the emergency department 
before (Cohort 1) or after (Cohort 2) lowering the high-sensitivity cardiac troponin T (hs-cTnT) cutoff. 
Dyspnea
Cohort 1 Cohort 2 P 
Number of ED visits 7802 6691
Age [years] 76 (63–84) 76 (64–85) 0.95
Male sex 45.3% 45.3% 0.97
Dyspnea NA NA NA
Admission 71.3% 66.3% < 0.001
Hospital cost among admitted (mean DRG weigh/patient visit) 0.67 0.39 < 0.001
Admission if hs-cTnT analyzed on ED 73.7% 70.2% 0.002
Admission time (days ± SD) 5.4 ± 5.2 5.3 ± 5.1 0.15
hs-cTnT sampling frequency 66.0% 42.2% < 0.001
Median baseline hs-cTnT level [ng/L] 19 (6–42) 22 (9–44) < 0.001
Baseline hs-cTnT level 14–40 ng/L among analysed on ED 31.4% 36.7% < 0.001
Return to ED within 30 days 29.9% 32.7% < 0.001
NSTEMI diagnosis†
NSTEMI (%) 2.3% 1.8% 0.046
NSTEMI if baseline hs-cTnT 14–40 ng/L 1.7% 2.8% 0.052
NSTEMI if baseline hs-cTnT > 40 ng/L 10.3% 10.3% 1.000
Primary or secondary diagnosis†
Unstable AP 0.1% 0.1% 0.44
Stable AP 1.0% 1.0% 1.000
Heart failure 13.0% 12.0% 0.074
Interventions†
Coronary angiography 0.9% 1.1% 0.11
Percutaneous coronary intervention 0.2% 0.3% 0.48
All cause mortality
30 day 8.4% 8.7% 0.49
180 day 19.3% 20.4% 0.091
All cause mortality if not analyzed with hs-cTnT
30 day 5.3% 7.6% < 0.001
180 day 16.0% 20.4% < 0.001
†Only patients that were admitted; AP — angina pectoris; DRG — diagnosis related group, a way to assess the hospital coast related to  
different diagnosis group; ED — emergency room; NA — not applicable; NSTEMI — non-ST-segment elevation myocardial infarction
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and mortality decreased among admitted patients 
analyzed with at least one hs-cTnT sample after 
lowering the hs-cTnT cutoff point. When both 
sampled and non-sampled patients were analyzed, 
no change in NSTEMI frequency or mortality was 
found. This agrees with other studies that did not 
find an effect on mortality following introduction 
of a more sensitive cTn assay in clinical routine 
[20, 21].
The present interpretation is that decreased 
hs-cTnT cutoff point may have resulted in a more 
restrictive selection of patients to assess hs-cTnT 
levels in order to limit false positive results. This 
may have resulted in sampling bias, with the selec-
tion of younger patients with fewer comorbidities. 
The new medical protocol that was implemented 
when hs-cTnT cutoff was lowered to the 99th per-
centile stated that the only indication of a hs-cTnT 
test is suspicion of acute cardiac damage [22] and 
alerted the attending physician to the fact that old 
age [6, 15], decreased kidney function [23–25] and 
heart failure [26, 27] can result in false positive 
hs-cTnT results. This could be an explanation 
behind decreased hs-cTnT sampling frequency 
Figure 2. Graphical representation of selected data before (Cohort 1) and after (Cohort 2) lowering of the high-
sensitivity cardiac troponin T (hs-cTnT) cutoff point from 40 ng/L to 14 ng/L; A. The percentage of all, chest pain or 
dyspnea patients analyzed with at least one hs-cTnT sample on the emergency department (ED); B. Non-ST-segment 
elevation myocardial infarction (NSTEMI) frequency among patients with baseline hs-cTnT level 14–40 ng/L or above 
40 ng/L. Data from all patients or chest pain patients are shown; C. All cause death at 180 days after the ED visit; 
D. Recorded heart diagnosis except for hypertension among patients that were not analyzed with hs-cTnT during 
the ED visit or hospital stay. Data for all patients, chest pain patients and dyspnea patients are shown; **p < 0.01; 
NS — not significant.
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especially among patients with dyspnea, who more 
often present with comorbidities and at older age. 
The more restrictive use of hs-cTnT sampling and 
admissions resulted in a decrease in hospital costs 
with a neutral effect on overall mortality, also when 
patients who were sent home from the ED were 
analyzed separately (data not shown). 
On the other hand, an increased mortality was 
observed among patients who were not analyzed 
with a hs-cTnT sample, a higher return to the ED 
within 30 days in combination with a slight increase 
in MI frequency among patients that did return. 
This can potentially be explained by the fact that 
non-sampled patients were older and had more 
comorbidities after lowering the hs-cTnT cutoff. It 
is therefore unclear if these patients would benefit 
from more sampling and intervention. This is the 
subject of future studies from the present group. 
Figure 3. Analysis of non-ST-segment elevation myocardial infarction (NSTEMI) patient data before (Cohort 1) and 
after (Cohort 2) lowering high-sensitivity cardiac troponin T (hs-cTnT) cutoff point from 40 ng/L to 14 ng/L; A. Frequency 
of patients with NSTEMI with hs-cTnT levels below 40 ng/L after different times of hs-cTnT sampling; B. Median 
relative change in hs-cTnT levels during 24 h in patients with NSTEMI with baseline hs-cTnT levels between 14 ng/L 
and 40 ng/L or above 40 ng/L; C. Percentage of patients with NSTEMI with in-hospital hs-cTnT levels below baseline 
hs-cTnT levels (declining pattern) in patients with baseline hs-cTnT levels between 14 ng/L and 40 ng/L or above 
40 ng/L;**p < 0.001; NS — not significant.
Table 5. Characteristics of chest pain or dyspnea patients with non-ST-segment elevation myocardial 
infarction (NSTEMI) diagnosis and baseline high-sensitivity cardiac troponin T (hs-cTnT) sample ana-
lyzed in the emergency department before (Cohort 1) or after (Cohort 2) lowering the hs-cTnT cutoff.
Cohort 1 Cohort 2 P 
Number of NSTEMI patients 741 648
Age [years] 78 (67–87) 76 (65–86) 0.014
Dyspnea 21.7% 16.4% 0.012
Male sex 57.2% 54.3% 0.28
Hospital cost (mean DRG weight ± SD) 1.16 ± 0.49 1.03 ± 0.44 < 0.001
hs-cTnTn levels
Baseline hs-cTnT [ng/L] 79 (35–223) 51 (25–151) < 0.001
Max hs-cTnT [ng/L] 239 (104–599) 156 (62–438) < 0.001
Interventions
Coronary angiography 24.2% 33.0% < 0.001
Percutaneous coronary intervention 13.1% 14.8% 0.39
All cause mortality
30 day 8.1% 6.2% 0.18
180 day 17.5% 13.9% 0.066
DRG — diagnosis related group, a way to assess the hospital coast related to different diagnosis group
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Thus, this experience underscores the impor-
tance of a predefined protocol on how to deal with 
unspecific troponin elevation unrelated to MI [28, 
29] before implementing the 99th cTnT percentile 
as the diagnostic cutoff point. 
This data also show indirect evidence that pa-
tients with NSTEMI with low and stable hs-cTnT 
levels were more often missed in Cohort 1, when 
40 ng/L instead of 14 ng/L was used as a diagnostic 
cutoff point.
Firstly, the frequency of patients with NSTEMI 
with low hs-cTnT levels increased following the 
introduction of 14 ng/L as a diagnostic cutoff point. 
Secondly, when 14 ng/L was used as a cutoff 
point, patients with NSTEMI more often had 
baseline hs-cTnT levels below 40 ng/L with stable 
or declining hs-cTnT levels. In contrast, these 
patients were rare when the cutoff point was 
40 ng/L, possibly because patients with NSTEMI 
having stable or declining hs-cTnT levels below 
40 ng/L were more often missed when 40 ng/L was 
used as a cutoff.  
On the other hand, it was also observed that 
the frequency of NSTEMI among chest pain pa-
tients with a baseline hs-cTnT above 40 ng/L 
decreased, possibly due to more restrictive use 
of NSTEMI diagnosis, as dictated by the altered 
medical protocol. This reciprocal change, with an 
increased NSTEMI frequency among patients with 
low hs-cTnT levels and a decreased NSTEMI fre-
quency when baseline hs-cTnT levels were high, 
is likely the reason behind the unchanged overall 
NSTEMI frequency after lowering the hs-cTnT 
cutoff point.  
Limitations of the study
This study has several limitations. It was 
a service evaluation of retrospective data and not 
designed to examine only the effect of implemen-
tation of the 99th hs-cTnT percentile. During the 
4 year study, clinical routines changed, as described 
in Materials and Methods, and it is not possible to 
attribute all the effects in hospital and laboratory 
statistics to lowering of  hs-cTnT cutoff point. In 
addition, the NSTEMI diagnosis was in many cases 
a clinical diagnosis and not carried out according 
to a predefined protocol to provide hs-cTnT-inde-
pendent evidence of myocardial damage of ischemic 
origin. No adjudication of NSTEMI diagnoses were 
done. In addition, there was a drift in the hs-cTnT 
assay calibration resulting in an underestimation 
of hs-cTnT levels a year before and 4 months after 
lowering the hs-cTnT cutoff. It is unclear if this 
might have affected clinical judgements [30]. The 
study also does not include important prognostic 
variables like metabolic syndrome, body mass in-
dex, waist circumference, serum cholesterol levels 
and family history of important diseases. However, 
the large sample size and the use of the same hs-
cTnT assay in clinical routines both before and 
after the lowering of hs-cTnT cutoff point offered 
a unique possibility to assess the implications of 
a lowered hs-cTnT cutoff point down to the 99th 
percentile in a real clinical situation.
Conclusions
In summary, our service report indicates that, 
after implementation of the 99th cTnT percentile 
as the diagnostic cutoff point for MI, hs-cTnT 
sampling routines changed, admission rates de-
creased, 30-day mortality and NSTEMI frequency 
was unchanged.
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